| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

6-9 February 2023

BIO CEO & Investor Conference 2023

New York Marriot Marquis

NY

United States

6 February 2023

ORYZON to give updates on corporate progress in February-March

18 January 2023

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

24 January 2023

Invest Securities Biomed Forum 2023

Paris

France

9-12 January 2023

41st Annual J.P. Morgan Healthcare Conference

Westin St. Francis Hotel, San Francisco

CA

United States

9-11 January 2023

12th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel, San Francisco

CA

United States

8 January 2023

6th Sachs Annual Neuroscience Innovation Forum

Marine’s Memorial Club, San Francisco

CA

United States

5 January 2023

ORYZON to give updates on corporate progress in January

16 December 2022

ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches

12 December 2022

ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022

Pagination

First page «
Previous page ‹
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel